cAMP	O
inducibility	O
of	O
transcriptional	B-protein
repressor	I-protein
ICER	B-protein
in	O
developing	O
and	O
mature	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jul	O
23	O
;	O
93	O
(	O
15	O
)	O
:	O
8154	O
]	O

Stimulation	O
of	O
the	O
cAMP-dependent	O
signaling	O
pathway	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
and	O
effector	O
functions	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
ability	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
form	O
high	O
intracellular	O
levels	O
of	O
cAMP	O
is	O
acquired	O
during	O
development	O
in	O
the	O
human	O
thymus	O
and	O
is	O
retained	O
by	O
the	O
majority	O
of	O
mature	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Here	O
we	O
show	O
that	O
elevated	O
cAMP	O
levels	O
in	O
T	B-cell_type
cells	I-cell_type
correlate	O
with	O
the	O
expression	O
of	O
the	O
potent	B-protein
transcriptional	I-protein
repressor	I-protein
ICER	B-protein
(	O
inducible	B-protein
cAMP	I-protein
early	I-protein
repressor	I-protein
)	O
previously	O
described	O
in	O
the	O
hypothalamic-pituitary-gonadal	O
axis	O
.	O

Further	O
,	O
in	O
transcriptional	O
assays	O
in	O
vivo	O
,	O
ICER	B-protein
inhibits	O
calcineurin	B-protein
-mediated	O
expression	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
as	O
well	O
as	O
Tax	B-protein
-mediated	O
transactivation	O
of	O
the	O
human	B-DNA
T-lymphotropic	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Thus	O
,	O
the	O
induction	O
of	O
ICER	B-protein
in	O
T	B-cell_type
cells	I-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
cAMP-induced	O
quiescence	O
and	O
the	O
persistent	O
latency	O
of	O
HTLV-I	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

93	NULL
,	NULL
pp	NULL
.	NULL

3536-3541	NULL
,	NULL
April	NULL
1996	NULL
Medical	NULL
Sciences	NULL
cAMP	NULL
inducibility	NULL
of	NULL
transcriptional	NULL
repressor	NULL
ICER	NULL
in	NULL
developing	NULL
and	NULL
mature	NULL
human	NULL
T	NULL
lymphocytes	NULL
JosEr	NULL
BODOR	NULL
*T	NULL
,	NULL
ANNA-LENA	NULL
Jack	NULL
L.	NULL
STRoMINGER	NULL
$	NULL
,	NULL
anD	NULL
JoEL	NULL
F.	NULL
HasenEr*t§	NULL
*Laboratory	NULL
of	NULL
Molecular	NULL
Endocrinology	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
,	NULL
``	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
and	NULL
*Division	NULL
of	NULL
Tumor	NULL
Virology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02114	NULL
Communicated	NULL
by	NULL
Matthew	NULL
Meselson	NULL
,	NULL
Harvard	NULL
University	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
,	NULL
December	NULL
19	NULL
,	NULL
1995	NULL
(	NULL
received	NULL
for	NULL
review	NULL
August	NULL
22	NULL
,	NULL
1995	NULL
)	NULL
ABSTRACT	NULL
Stimulation	NULL
of	NULL
the	NULL
cAMP-dependent	NULL
signaling	NULL
pathway	NULL
exerts	NULL
an	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
proliferation	NULL
and	NULL
effector	NULL
functions	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
form	NULL
high	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
is	NULL
acquired	NULL
during	NULL
development	NULL
in	NULL
the	NULL
human	NULL
thymus	NULL
and	NULL
is	NULL
retained	NULL
by	NULL
the	NULL
majority	NULL
of	NULL
mature	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
elevated	NULL
cAMP	NULL
levels	NULL
in	NULL
T	NULL
cells	NULL
correlate	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
potent	NULL
transcriptional	NULL
repressor	NULL
ICER	NULL
(	NULL
inducible	NULL
cAMP	NULL
early	NULL
repressor	NULL
)	NULL
previously	NULL
described	NULL
in	NULL
the	NULL
hypothalamic	NULL
,	NULL
pituitary-gonadal	NULL
axis	NULL
.	NULL

Further	NULL
,	NULL
in	NULL
transcriptional	NULL
assays	NULL
in	NULL
vivo	NULL
,	NULL
ICER	NULL
inhibits	NULL
calcineurin-mediated	NULL
expression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
as	NULL
well	NULL
as	NULL
Tax-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-1D	NULL
)	NULL
promoter	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
ICER	NULL
in	NULL
T	NULL
cells	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
cAMP-induced	NULL
quiescence	NULL
and	NULL
the	NULL
persistent	NULL
latency	NULL
of	NULL
HTLV-I	NULL
.	NULL

The	NULL
inhibitory	NULL
effects	NULL
of	NULL
the	NULL
second	NULL
messenger	NULL
cAMP	NULL
on	NULL
T-cell	NULL
proliferation	NULL
and	NULL
effector	NULL
functions	NULL
are	NULL
well	NULL
recognized	NULL
(	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
the	NULL
inhibitory	NULL
effects	NULL
occur	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
novel	NULL
cA	NULL
MP-inducible	NULL
transcriptional	NULL
repressor	NULL
protein	NULL
has	NULL
been	NULL
described	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

This	NULL
transrepressor	NULL
,	NULL
ICER	NULL
,	NULL
is	NULL
expressed	NULL
in	NULL
neuroendocrine	NULL
tissues	NULL
such	NULL
as	NULL
the	NULL
pineal	NULL
,	NULL
pituitary	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
,	NULL
and	NULL
thyroid	NULL
(	NULL
4	NULL
)	NULL
glands	NULL
under	NULL
rhythmic	NULL
,	NULL
circadian	NULL
control	NULL
.	NULL

ICER	NULL
binds	NULL
to	NULL
cAMP	NULL
response	NULL
elements	NULL
(	NULL
CREs	NULL
)	NULL
that	NULL
diverge	NULL
considerably	NULL
from	NULL
the	NULL
canonical	NULL
CRE	NULL
motif	NULL
,	NULL
TGACGTCA	NULL
,	NULL
and	NULL
thereby	NULL
inhibits	NULL
CRE-binding	NULL
transactivator	NULL
proteins	NULL
.	NULL

These	NULL
CREs	NULL
include	NULL
the	NULL
cAMP	NULL
autoregulatory	NULL
response	NULL
elements	NULL
located	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
ICER	NULL
gene	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
ICER	NULL
gene	NULL
is	NULL
stimulated	NULL
by	NULL
cA	NULL
MP	NULL
-activated	NULL
transcription	NULL
factors	NULL
and	NULL
is	NULL
then	NULL
repressed	NULL
by	NULL
negative	NULL
autoregulatory	NULL
feedback	NULL
,	NULL
thereby	NULL
establishing	NULL
a	NULL
circadian	NULL
control	NULL
of	NULL
ICER	NULL
gene	NULL
expression	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
known	NULL
circadian	NULL
fluctuations	NULL
in	NULL
the	NULL
proliferation	NULL
and	NULL
activities	NULL
of	NULL
lymphocytes	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
high	NULL
levels	NULL
of	NULL
intracellular	NULL
cAMP	NULL
in	NULL
developing	NULL
T	NULL
lymphocytes	NULL
could	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
ICER	NULL
and	NULL
so	NULL
implicate	NULL
a	NULL
potential	NULL
role	NULL
for	NULL
ICER	NULL
in	NULL
the	NULL
observed	NULL
inhibitory	NULL
effects	NULL
of	NULL
cAMP	NULL
on	NULL
mature	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
prostaglandin	NULL
E	NULL
;	NULL
(	NULL
PGE	NULL
)	NULL
and	NULL
forskolin	NULL
,	NULL
known	NULL
agonists	NULL
for	NULL
cAMP	NULL
signaling	NULL
,	NULL
rapidly	NULL
induce	NULL
ICER	NULL
mRNA	NULL
in	NULL
human	NULL
medullary	NULL
thymocytes	NULL
and	NULL
mature	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocytes	NULL
,	NULL
but	NULL
not	NULL
in	NULL
immature	NULL
cortical	NULL
thymocytes	NULL
or	NULL
peripheral	NULL
B	NULL
lymphocytes	NULL
.	NULL

Further	NULL
,	NULL
we	NULL
show	NULL
that	NULL
in	NULL
transfection	NULL
expression	NULL
experiments	NULL
in	NULL
vivo	NULL
,	NULL
ICER	NULL
inhibits	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter	NULL
as	NULL
well	NULL
as	NULL
the	NULL
promoter	NULL
for	NULL
the	NULL
human	NULL
T-cell-specific	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
.	NULL

Inasmuch	NULL
as	NULL
IL-2	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
ICER	NULL
may	NULL
be	NULL
a	NULL
mechanism	NULL
to	NULL
explain	NULL
the	NULL
antiproliferative	NULL
effects	NULL
of	NULL
cAMP	NULL
signaling	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
capability	NULL
for	NULL
ICER	NULL
to	NULL
bind	NULL
to	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
divergent	NULL
CREs	NULL
raises	NULL
the	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

3536	NULL
possibility	NULL
that	NULL
ICER	NULL
may	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
or	NULL
many	NULL
genes	NULL
in	NULL
response	NULL
to	NULL
cAMP	NULL
signaling	NULL
during	NULL
T-cell	NULL
development	NULL
and/or	NULL
proliferation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Preparation	NULL
of	NULL
Human	NULL
Thymocytes	NULL
and	NULL
Peripheral	NULL
Blood	NULL
T	NULL
and	NULL
B	NULL
Lymphocytes	NULL
.	NULL

Human	NULL
thymus	NULL
glands	NULL
were	NULL
obtained	NULL
from	NULL
children	NULL
(	NULL
ages	NULL
3	NULL
months	NULL
to	NULL
4	NULL
years	NULL
)	NULL
undergoing	NULL
corrective	NULL
cardiac	NULL
surgery	NULL
.	NULL

Thymocytes	NULL
were	NULL
fractionated	NULL
over	NULL
discontinuous	NULL
Percoll	NULL
gradients	NULL
(	NULL
Pharmacia	NULL
)	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Cells	NULL
with	NULL
densities	NULL
of	NULL
1.060	NULL
<	NULL
o	NULL
<	NULL
1.070	NULL
and	NULL
P	NULL
>	NULL
1.070	NULL
were	NULL
collected	NULL
and	NULL
classified	NULL
into	NULL
large	NULL
and	NULL
small	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

Cell	NULL
size	NULL
profiles	NULL
were	NULL
determined	NULL
on	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
using	NULL
a	NULL
linear	NULL
scale	NULL
.	NULL

Cell	NULL
surface	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
was	NULL
performed	NULL
(	NULL
8	NULL
)	NULL
,	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
conjugated	NULL
monoclonal	NULL
antibody	NULL
anti-CD3	NULL
(	NULL
UCHT1	NULL
,	NULL
Immunotech	NULL
,	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
,	NULL
anti-CD4-PE	NULL
(	NULL
MT310	NULL
,	NULL
Dako	NULL
)	NULL
,	NULL
or	NULL
anti-CD8-FITC	NULL
(	NULL
SK1	NULL
,	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Buffy-coat	NULL
leukocytes	NULL
were	NULL
obtained	NULL
from	NULL
healthy	NULL
adult	NULL
blood	NULL
donors	NULL
,	NULL
and	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
by	NULL
using	NULL
Ficoll-Hypaque	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

Monocytes	NULL
were	NULL
depleted	NULL
by	NULL
adherence	NULL
to	NULL
plastic	NULL
,	NULL
2	NULL
X	NULL
45	NULL
min	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO/BRL	NULL
)	NULL
at	NULL
37°C	NULL
.	NULL

Recovered	NULL
cells	NULL
were	NULL
depleted	NULL
of	NULL
B	NULL
cells	NULL
by	NULL
using	NULL
magnetic	NULL
cell	NULL
sorting	NULL
(	NULL
MACS	NULL
,	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Staining	NULL
with	NULL
anti-CD19-microbeads	NULL
and	NULL
separations	NULL
on	NULL
MACS	NULL
columns	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
instructions	NULL
,	NULL
except	NULL
that	NULL
the	NULL
buffer	NULL
used	NULL
was	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
1.0	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
.	NULL

The	NULL
T-cell-enriched	NULL
populations	NULL
typically	NULL
contained	NULL
less	NULL
than	NULL
4	NULL
%	NULL
CD20*B	NULL
cells	NULL
,	NULL
less	NULL
than	NULL
3	NULL
%	NULL
CD14*	NULL
monocytes	NULL
,	NULL
and	NULL
15-23	NULL
%	NULL
CD16*	NULL
natural	NULL
killer	NULL
cells	NULL
,	NULL
as	NULL
revealed	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

cAMP	NULL
Assay	NULL
.	NULL

To	NULL
measure	NULL
cAMP	NULL
formation	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
agonists	NULL
and	NULL
incubated	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
1.0	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
.	NULL

Measurements	NULL
of	NULL
intracellular	NULL
cAMP	NULL
concentrations	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
established	NULL
procedures	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
standard	NULL
deviations	NULL
of	NULL
average	NULL
values	NULL
calculated	NULL
from	NULL
three	NULL
or	NULL
more	NULL
independent	NULL
experiments	NULL
.	NULL

Reverse	NULL
Transcription	NULL
(	NULL
RT	NULL
)	NULL
-PCR	NULL
Cloning	NULL
and	NULL
Sequencing	NULL
.	NULL

Human	NULL
Jurkat	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
0.1	NULL
mM	NULL
forskolin	NULL
were	NULL
harvested	NULL
3	NULL
h	NULL
post-induction	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
and	NULL
subjected	NULL
to	NULL
RT-PCR	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
5	NULL
and	NULL
3	NULL
'	NULL
primers	NULL
were	NULL
:	NULL
5-ATG	NULL
GCT	NULL
GTA	NULL
ACT	NULL
GGA	NULL
GAT	NULL
GAA	NULL
ACT-3	NULL
'	NULL
and	NULL
5'-CTA	NULL
ATC	NULL
TGT	NULL
TTT	NULL
GGG	NULL
AGA	NULL
GCA	NULL
AAT	NULL
GTC-3	NULL
'	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
primers	NULL
were	NULL
selected	NULL
to	NULL
begin	NULL
with	NULL
the	NULL
start	NULL
codon	NULL
(	NULL
ATG	NULL
)	NULL
and	NULL
stop	NULL
codon	NULL
(	NULL
antisense	NULL
CTA	NULL
)	NULL
,	NULL
Abbreviations	NULL
:	NULL
ICER	NULL
,	NULL
inducible	NULL
cAMP	NULL
early	NULL
repressor	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
HTLV-I	NULL
,	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
;	NULL
PGE	NULL
;	NULL
,	NULL
prostaglandin	NULL
E	NULL
;	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
;	NULL
bZIP	NULL
,	NULL
basic	NULL
leucine	NULL
zipper	NULL
;	NULL
PKA	NULL
,	NULL
protein	NULL
kinase	NULL
A	NULL
;	NULL
CRE	NULL
,	NULL
cAMP	NULL
response	NULL
element	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
``	NULL
12-O-tetradecanoylphorbol	NULL
13-acetate	NULL
``	NULL
)	NULL
.	NULL

$	NULL
To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
at	NULL
:	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Endocrinology	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
,	NULL
WEL	NULL
320	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02114	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Bodor	NULL
et	NULL
al	NULL
.	NULL

respectively	NULL
.	NULL

RT-PCR	NULL
cloning	NULL
and	NULL
sequencing	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
standard	NULL
procedures	NULL
(	NULL
10	NULL
)	NULL
.	NULL

RNase	NULL
Protection	NULL
Analysis	NULL
.	NULL

RNA	NULL
extraction	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
10	NULL
)	NULL
.	NULL

RNA	NULL
probe	NULL
1	NULL
is	NULL
generated	NULL
from	NULL
pCREM-hRIBO3	NULL
by	NULL
BamHI	NULL
digestion	NULL
and	NULL
in	NULL
vitro	NULL
transcription	NULL
.	NULL

RNA	NULL
probe	NULL
2	NULL
was	NULL
prepared	NULL
from	NULL
pJL5	NULL
by	NULL
Xho	NULL
I	NULL
digestion	NULL
and	NULL
corresponds	NULL
to	NULL
full-length	NULL
cDNA	NULL
of	NULL
human	NULL
ICER	NULL
II	NULL
.	NULL

In	NULL
the	NULL
data	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
an	NULL
RNA	NULL
probe	NULL
complementary	NULL
to	NULL
human	NULL
a-globin	NULL
was	NULL
included	NULL
with	NULL
the	NULL
ICER	NULL
RNA	NULL
probe	NULL
to	NULL
serve	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

RNA	NULL
probes	NULL
,	NULL
uniformly	NULL
labeled	NULL
with	NULL
[	NULL
«	NULL
-	NULL
>	NULL
°P	NULL
]	NULL
JCTP	NULL
,	NULL
were	NULL
prepared	NULL
by	NULL
using	NULL
reagents	NULL
from	NULL
an	NULL
RNA	NULL
probe	NULL
kit	NULL
(	NULL
Ambion	NULL
)	NULL
.	NULL

These	NULL
probes	NULL
were	NULL
used	NULL
for	NULL
RNase	NULL
protection	NULL
studies	NULL
,	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
provided	NULL
by	NULL
Ambion	NULL
(	NULL
RPAII	NULL
Ribonuclease	NULL
Protection	NULL
Assay	NULL
kit	NULL
)	NULL
.	NULL

X-ray	NULL
films	NULL
were	NULL
scanned	NULL
and	NULL
evaluated	NULL
by	NULL
densitometry	NULL
with	NULL
ImaAGE-QUANT	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

Results	NULL
have	NULL
been	NULL
reproduced	NULL
in	NULL
several	NULL
independent	NULL
experiments	NULL
.	NULL

Immunocytochemistry	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
forskolin	NULL
(	NULL
0.1	NULL
mM	NULL
)	NULL
,	NULL
attached	NULL
to	NULL
slides	NULL
after	NULL
24	NULL
h	NULL
by	NULL
using	NULL
a	NULL
micro-cytocentrifuge	NULL
(	NULL
StatSpin	NULL
,	NULL
Norwood	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
and	NULL
fixed	NULL
for	NULL
5	NULL
'	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
in	NULL
saline	NULL
.	NULL

Immunocytochemistry	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
Vectastain	NULL
horseradish	NULL
peroxidase	NULL
ABC	NULL
kit	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
.	NULL

The	NULL
ICER	NULL
-specific	NULL
antiserum	NULL
,	NULL
used	NULL
for	NULL
immunocytochemical	NULL
staining	NULL
,	NULL
was	NULL
raised	NULL
in	NULL
a	NULL
guinea	NULL
pig	NULL
(	NULL
Hazelton	NULL
Research	NULL
Products	NULL
,	NULL
Denver	NULL
,	NULL
PA	NULL
)	NULL
against	NULL
an	NULL
ICER-specific	NULL
peptide	NULL
(	NULL
Ala-Val-Thr-Gly-Asp-Glu-Thr-Gly-Gly-Cys	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
,	NULL
conjugated	NULL
to	NULL
keyhole	NULL
limpet	NULL
hemocyanin	NULL
.	NULL

Transient	NULL
Overexpression	NULL
in	NULL
Jurkat	NULL
T	NULL
Cells	NULL
.	NULL

Transfection	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
technique	NULL
.	NULL

Typ-ically	NULL
,	NULL
10	NULL
``	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
the	NULL
reporter	NULL
and	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
Tax	NULL
or	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
expression	NULL
vectors	NULL
.	NULL

Chloramphenicol	NULL
acetyltransferase	NULL
assays	NULL
and	NULL
quantification	NULL
methods	NULL
are	NULL
described	NULL
elsewhere	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
percent	NULL
conversion	NULL
of	NULL
[	NULL
'*CJchloramphenicol	NULL
to	NULL
its	NULL
acetylated	NULL
forms	NULL
(	NULL
Ac	NULL
)	NULL
was	NULL
quantified	NULL
by	NULL
using	NULL
a	NULL
Betagen	NULL
Betascope	NULL
(	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
here	NULL
are	NULL
representative	NULL
of	NULL
a	NULL
series	NULL
of	NULL
several	NULL
independent	NULL
experiments	NULL
.	NULL

RESULTS	NULL
AND	NULL
DISCUSSION	NULL
Maturation	NULL
of	NULL
PKA	NULL
Pathway	NULL
During	NULL
T-Cell	NULL
Development	NULL
in	NULL
Human	NULL
Thymus	NULL
.	NULL

Thymus	NULL
glands	NULL
were	NULL
obtained	NULL
from	NULL
children	NULL
undergoing	NULL
corrective	NULL
heart	NULL
surgery	NULL
,	NULL
and	NULL
thymocytes	NULL
were	NULL
separated	NULL
by	NULL
centrifugation	NULL
through	NULL
Percoll	NULL
gradients	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Fractionated	NULL
thymocytes	NULL
consisted	NULL
of	NULL
either	NULL
small	NULL
,	NULL
immature	NULL
cortical	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A-C	NULL
)	NULL
,	NULL
or	NULL
large	NULL
cells	NULL
,	NULL
containing	NULL
mature	NULL
medullary	NULL
or	NULL
CD4~8*	NULL
thymocytes	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
4	NULL
,	NULL
B	NULL
,	NULL
and	NULL
D	NULL
)	NULL
(	NULL
12	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
their	NULL
differences	NULL
,	NULL
these	NULL
fractionated	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
adenylyl	NULL
cyclase	NULL
agonists	NULL
forskolin	NULL
or	NULL
PGE	NULL
;	NULL
within	NULL
12	NULL
h	NULL
of	NULL
obtaining	NULL
the	NULL
thymus	NULL
gland	NULL
.	NULL

Both	NULL
agonists	NULL
caused	NULL
a	NULL
striking	NULL
elevation	NULL
of	NULL
cAMP	NULL
levels	NULL
in	NULL
medullary	NULL
thymocytes	NULL
,	NULL
but	NULL
relatively	NULL
low	NULL
elevations	NULL
in	NULL
small	NULL
cortical	NULL
thymocytes	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
E	NULL
and	NULL
F	NULL
)	NULL
.	NULL

PGE	NULL
;	NULL
or	NULL
forskolin	NULL
also	NULL
markedly	NULL
stimulated	NULL
cAMP	NULL
levels	NULL
in	NULL
mature	NULL
PBL	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
little	NULL
or	NULL
no	NULL
response	NULL
was	NULL
observed	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
G	NULL
and	NULL
H	NULL
)	NULL
.	NULL

These	NULL
large	NULL
differences	NULL
in	NULL
the	NULL
responses	NULL
of	NULL
separated	NULL
thymocytes	NULL
led	NULL
us	NULL
to	NULL
examine	NULL
whether	NULL
the	NULL
elevations	NULL
of	NULL
cAMP	NULL
that	NULL
are	NULL
measured	NULL
in	NULL
medullary	NULL
thymocytes	NULL
and	NULL
mature	NULL
PBL	NULL
T	NULL
cells	NULL
could	NULL
be	NULL
sufficient	NULL
to	NULL
induce	NULL
the	NULL
transcriptional	NULL
repressor	NULL
ICER	NULL
.	NULL

Human	NULL
ICER	NULL
Sequence	NULL
Is	NULL
Highly	NULL
Conserved	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
elevated	NULL
levels	NULL
of	NULL
intracellular	NULL
cAMP	NULL
in	NULL
medullary	NULL
thymocytes	NULL
induce	NULL
ICER	NULL
,	NULL
all	NULL
four	NULL
isoforms	NULL
of	NULL
human	NULL
ICER	NULL
were	NULL
cloned	NULL
by	NULL
RT-PCR	NULL
from	NULL
forskolin-treated	NULL
human	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
were	NULL
sequenced	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Alignment	NULL
of	NULL
the	NULL
human	NULL
and	NULL
mouse	NULL
sequences	NULL
of	NULL
ICER	NULL
II	NULL
shows	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
conservation	NULL
at	NULL
both	NULL
the	NULL
nucleotide	NULL
and	NULL
amino	NULL
acid	NULL
levels	NULL
,	NULL
particularly	NULL
in	NULL
the	NULL
bZIP	NULL
domains	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
ICER	NULL
Correlates	NULL
with	NULL
cAMP	NULL
Response	NULL
in	NULL
Medullary	NULL
Thymocytes	NULL
.	NULL

The	NULL
ICER	NULL
cDNAs	NULL
allowed	NULL
for	NULL
the	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
3537	NULL
A	NULL
B	NULL
5	NULL
:	NULL
w	NULL
m	NULL
|	NULL
X	NULL
A	NULL
2	NULL
§	NULL
4	NULL
\Sr	NULL
s	NULL
=	NULL
/	NULL
WJ	NULL
_j	NULL
|	NULL
/	NULL
\	NULL
CC	NULL
-	NULL
}	NULL
*	NULL
Large	NULL
m	NULL
f	NULL
ge	NULL
O	NULL
~	NULL
f	NULL
+	NULL
0	NULL
-	NULL
160	NULL
'	NULL
”	NULL
00	NULL
100	NULL
HIV	NULL
HI	NULL
)	NULL
:	NULL
NIH	NULL
”	NULL
104	NULL
FORWARD	NULL
SCATTER	NULL
(	NULL
FSC	NULL
)	NULL
-	NULL
CD3	NULL
EXPRESSION	NULL
104	NULL
C	NULL
D	NULL
11	NULL
?	NULL

%	NULL
3°	NULL
253	NULL
j	NULL
sre	NULL
*	NULL
Z	NULL
4	NULL
O	NULL
193	NULL
]	NULL
C	NULL
yi	NULL
.	NULL

&	NULL
C	NULL
oom	NULL
|	NULL
hte	NULL
.	NULL

>	NULL
&	NULL
102	NULL
3	NULL
pod	NULL
%	NULL
3	NULL
3	NULL
tha	NULL
iri	NULL
]	NULL
1	NULL
#	NULL
10144	NULL
2	NULL
os	NULL
4	NULL
]	NULL
Wirz	NULL
,	NULL
?	NULL

58	NULL
4	NULL
a	NULL
3	NULL
O	NULL
7	NULL
100	NULL
10	NULL
!	NULL

102	NULL
103	NULL
100	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
CD8	NULL
EXPRESSION	NULL
CD8	NULL
EXPRESSION	NULL
[	NULL
E	NULL
00	NULL
=	NULL
-_	NULL
thymocytes	NULL
F	NULL
}	NULL
g	NULL
p	NULL
I	NULL
;	NULL
JP	NULL
?	NULL

g	NULL
$	NULL
8	NULL
|	NULL
PGE	NULL
,	NULL
E	NULL
Medullary	NULL
|	NULL
[	NULL
Forskolin	NULL
|	NULL
:	NULL
8	NULL
9	NULL
15	NULL
|-	NULL
f	NULL
'	NULL
ﬁ	NULL
I	NULL
{	NULL
pq	NULL
cortical	NULL
FIT	NULL
1	NULL
%	NULL
15C	NULL
:	NULL
>	NULL
s	NULL
ma	NULL
~	NULL
'	NULL
1	NULL
440	NULL
>	NULL
5	NULL
...	NULL
UA	NULL
A	NULL
1	NULL
€	NULL
S	NULL
to	NULL
L	NULL
‘	NULL
L.	NULL
ﬂ	NULL
“	NULL
a	NULL
.	NULL

§	NULL
|	NULL
|	NULL
I|	NULL
_	NULL
|	NULL
»	NULL
&	NULL
$	NULL
``	NULL
*I	NULL
|	NULL
Eu	NULL
Pret	NULL
‘	NULL
yl	NULL
l	NULL
yp	NULL
4	NULL
dio	NULL
<	NULL
i	NULL
>	NULL
|	NULL
s	NULL
t	NULL
|	NULL
|	NULL
y	NULL
|	NULL
[	NULL
sut	NULL
l	NULL
ke	NULL
.	NULL

Kl	NULL
...	NULL
ctv	NULL
|	NULL
EA	NULL
I	NULL
PA	NULL
|	NULL
bwa	NULL
1	NULL
,	NULL
pf	NULL
errr	NULL
|	NULL
Ga	NULL
PERIPHERAL	NULL
BLOGD	NULL
LyMPHocYTES	NULL
H	NULL
}	NULL
PGE	NULL
,	NULL
4L	NULL
ag+	NULL
,	NULL
Forskolin	NULL
|	NULL
!	NULL
``	NULL

''	NULL
3	NULL
[	NULL
|	NULL
%	NULL
BM	NULL
:	NULL
{	NULL
75	NULL
J	NULL
L_L	NULL
‘	NULL
_m	NULL
I	NULL
ham	NULL
|	NULL
ham	NULL
|	NULL
,	NULL
MINUTES	NULL
cAMP	NULL
pMol/10®	NULL
cells	NULL
cAMP	NULL
pMol/10®	NULL
cells	NULL
Fig	NULL
.	NULL

1.	NULL
.	NULL

Stimulation	NULL
of	NULL
cAMP	NULL
levels	NULL
in	NULL
thymocytes	NULL
and	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBLs	NULL
)	NULL
by	NULL
either	NULL
PGE	NULL
;	NULL
or	NULL
forskolin	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Forward	NULL
light	NULL
scatter	NULL
(	NULL
FSC	NULL
)	NULL
profiles	NULL
of	NULL
thymocyte	NULL
populations	NULL
obtained	NULL
after	NULL
separation	NULL
over	NULL
density	NULL
gradients	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
dotted	NULL
line	NULL
represents	NULL
small	NULL
,	NULL
low-density	NULL
thymocytes	NULL
;	NULL
the	NULL
filled	NULL
line	NULL
represents	NULL
large	NULL
,	NULL
high-density	NULL
thymocytes	NULL
.	NULL

Large	NULL
thymocytes	NULL
represent	NULL
approximately	NULL
15	NULL
%	NULL
of	NULL
total	NULL
thymocytes	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CD3	NULL
expression	NULL
of	NULL
small	NULL
and	NULL
large	NULL
thymocytes	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Small	NULL
thymocytes	NULL
expressed	NULL
no	NULL
detectable	NULL
,	NULL
or	NULL
relatively	NULL
low	NULL
,	NULL
levels	NULL
of	NULL
CD3	NULL
,	NULL
while	NULL
the	NULL
large	NULL
thymocyte	NULL
population	NULL
contained	NULL
cells	NULL
with	NULL
different	NULL
levels	NULL
of	NULL
CD3	NULL
expression	NULL
,	NULL
including	NULL
a	NULL
portion	NULL
of	NULL
CD3	NULL
``	NULL
#	NULL
``	NULL
cells	NULL
.	NULL

The	NULL
dotted	NULL
line	NULL
represents	NULL
a	NULL
negative	NULL
control	NULL
staining	NULL
with	NULL
an	NULL
isotype	NULL
matched	NULL
antibody	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Small	NULL
thymocytes	NULL
were	NULL
stained	NULL
with	NULL
anti-CD4-PE	NULL
and	NULL
anti-CD8-FITC	NULL
.	NULL

Shown	NULL
are	NULL
two-color	NULL
histograms	NULL
,	NULL
indicating	NULL
the	NULL
percentage	NULL
of	NULL
positive	NULL
cells	NULL
in	NULL
each	NULL
quad-rant	NULL
.	NULL

Small	NULL
thymocyte	NULL
populations	NULL
contained	NULL
more	NULL
than	NULL
98	NULL
%	NULL
cortical	NULL
CD4*CD8+*	NULL
thymocytes	NULL
.	NULL

(	NULL
D	NULL
)	NULL
The	NULL
flow	NULL
cytometry	NULL
of	NULL
large	NULL
thymocytes	NULL
reveals	NULL
an	NULL
enrichment	NULL
of	NULL
medullary	NULL
CD4*8~	NULL
and	NULL
CD4~8+*	NULL
thymocytes	NULL
.	NULL

Small	NULL
and	NULL
large	NULL
thymocytes	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
cortical	NULL
and	NULL
medullary	NULL
thymocytes	NULL
,	NULL
respectively	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Comparison	NULL
of	NULL
relative	NULL
cAMP	NULL
levels	NULL
in	NULL
the	NULL
medullary	NULL
versus	NULL
cortical	NULL
thymocytes	NULL
(	NULL
10°	NULL
cells	NULL
)	NULL
without	NULL
treatment	NULL
(	NULL
0	NULL
'	NULL
)	NULL
,	NULL
or	NULL
after	NULL
PGE	NULL
;	NULL
treatment	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
,	NULL
at	NULL
30-	NULL
,	NULL
60-	NULL
,	NULL
and	NULL
180-min	NULL
time	NULL
intervals	NULL
.	NULL

(	NULL
F	NULL
)	NULL
Relative	NULL
cAMP	NULL
levels	NULL
measured	NULL
in	NULL
medullary	NULL
or	NULL
cortical	NULL
thymocytes	NULL
after	NULL
forskolin	NULL
treatment	NULL
(	NULL
0.1	NULL
mM	NULL
)	NULL
.	NULL

(	NULL
G	NULL
)	NULL
Comparison	NULL
of	NULL
relative	NULL
cAMP	NULL
levels	NULL
in	NULL
human	NULL
PBL	NULL
T	NULL
cells	NULL
after	NULL
PGE	NULL
treatment	NULL
(	NULL
500	NULL
ng/mi	NULL
)	NULL
.	NULL

(	NULL
7	NULL
)	NULL
Relative	NULL
cAMP	NULL
levels	NULL
measured	NULL
in	NULL
PBL	NULL
T	NULL
cells	NULL
versus	NULL
B	NULL
cells	NULL
after	NULL
forskolin	NULL
treatment	NULL
(	NULL
0.1	NULL
mM	NULL
)	NULL
.	NULL

construction	NULL
of	NULL
RNase	NULL
protection	NULL
probes	NULL
specific	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
ICER	NULL
mRNAs	NULL
expressed	NULL
in	NULL
thymocytes	NULL
.	NULL

Treatment	NULL
of	NULL
medullary	NULL
thymocytes	NULL
with	NULL
forskolin	NULL
for	NULL
3	NULL
h	NULL
yielded	NULL
a	NULL
3538	NULL
Medical	NULL
Sciences	NULL
:	NULL
Bodor	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
A	NULL
[	NULL
--	NULL
DNA-Binding	NULL
|	NULL
GENE	NULL
Pi	NULL
Q-Rich	NULL
_	NULL
j	NULL
--	NULL
P-Box	NULL
--	NULL
-|	NULL
_	NULL
Q-Rich	NULL
pa	NULL
BR	NULL
LZe	NULL
LZb	NULL
s	NULL
r.	NULL
A	NULL
1	NULL
q	NULL
``	NULL
Rk	NULL
4	NULL
WK	NULL
TAA	NULL
TAG	NULL
ATG	NULL
ATG	NULL
v	NULL
mm	NULL
22	NULL
CTN	NULL
)	NULL
Ess	NULL
-	NULL
Te	NULL
Lum	NULL
2	NULL
I	NULL
for	NULL
:	NULL
mem	NULL
220	NULL
[	NULL
==	NULL
]	NULL
ICERIIy	NULL
Reems	NULL
To	NULL
(	NULL
-=	NULL
]	NULL
B	NULL
ICER-SPECIFIC	NULL
EXON	NULL
'	NULL
Y	NULL
MOUSE	NULL
G	NULL
HUMAN	NULL
-	NULL
1	NULL
ATG	NULL
GCT	NULL
GTA	NULL
ACT	NULL
GGA	NULL
GAT	NULL
GAA	NULL
ACT	NULL
GAT	NULL
GAG	NULL
GAA	NULL
ACT|GAN	NULL
CTT	NULL
GCC	NULL
CCA	NULL
AGT	NULL
CAC	NULL
ATG	NULL
57	NULL
10	NULL
Mo	NULL
A	NULL
-	NULL
vo	NULL
To	NULL
G0	NULL
Do	NULL
BE	NULL
T	NULL
Bo	NULL
EB	NULL
-T	NULL
Lo	NULL
A	NULL
-	NULL
Po	NULL
S0	NULL
Ho	NULL
OM	NULL
19	NULL
EXON	NULL
H	NULL
a	NULL
T	NULL
MOUSE	NULL
A	NULL
A	NULL
A	NULL
HUMAN	NULL
58	NULL
GCT	NULL
GCT	NULL
GCC	NULL
ACT	NULL
GGT	NULL
GAC	NULL
ATG	NULL
CCA	NULL
ACT	NULL
20	NULL
A	NULL
A	NULL
A	NULL
T	NULL
G	NULL
D	NULL
M	NULL
P	NULL
MOUSE	NULL
A	NULL
T	NULL
C	NULL
HUMAN	NULL
115	NULL
CCA	NULL
CAG	NULL
GGA	NULL
GTG	NULL
GTG	NULL
ATG	NULL
GCT	NULL
GCA	NULL
TCG	NULL
39	NULL
P	NULL
lel	NULL
G	NULL
v	NULL
v	NULL
M	NULL
A	NULL
A	NULL
MOUSE	NULL
T	NULL
G	NULL
G	NULL
HUMAN	NULL
172	NULL
GCA	NULL
GAA	NULL
GAA	NULL
GCA	NULL
ACA	NULL
CTC	NULL
AAA	NULL
CTA	NULL
GAG	NULL
58	NULL
A	NULL
E	NULL
E	NULL
A	NULL
T	NULL
R	NULL
K	NULL
R	NULL
TAC|CGG|	NULL
ATC	NULL
CGA	NULL
GCT	NULL
CCT	NULL
ACT	NULL
GCT	NULL
GCT	NULL
TTG	NULL
114	NULL
Y	NULL
R	NULL
I	NULL
R	NULL
A	NULL
P	NULL
T	NULL
A	NULL
A	NULL
L	NULL
38	NULL
A	NULL
c	NULL
c	NULL
A	NULL
A	NULL
CCC	NULL
GGA	NULL
AGT	NULL
TTG	NULL
CAC	NULL
AGT	NULL
CCC	NULL
CAG	NULL
CAG	NULL
CTG	NULL
171	NULL
P	NULL
G	NULL
S	NULL
L	NULL
H	NULL
S	NULL
P	NULL
o	NULL
o	NULL
L	NULL
57	NULL
EXON	NULL
H	NULL
-	NULL
EXON	NULL
I	NULL
'll	NULL
?	NULL

CTG	NULL
AGG	NULL
CTA	NULL
ATG	NULL
AAA	NULL
AAC	NULL
AGG	NULL
GAA	NULL
GCT	NULL
GCC	NULL
228	NULL
L	NULL
R	NULL
L	NULL
M	NULL
K	NULL
N	NULL
R	NULL
E	NULL
A	NULL
A	NULL
76	NULL
_	NULL
MoUsSE	NULL
HUMAN	NULL
229	NULL
AAA	NULL
GAA	NULL
TGT	NULL
CGA	NULL
CGT	NULL
CGA	NULL
AAG	NULL
AAA	NULL
GAA	NULL
77	NULL
K	NULL
E	NULL
C	NULL
R	NULL
R	NULL
R	NULL
K	NULL
K	NULL
BASIC	NULL
REGION	NULL
MOUSE	NULL
T	NULL
HUMAN	NULL
286	NULL
GTG	NULL
CTG	NULL
GAA	NULL
GTC	NULL
CAG	NULL
AAC	NULL
AAG	NULL
AAG	NULL
CTT	NULL
96	NULL
v	NULL
L	NULL
E	NULL
v	NULL
*	NULL
N	NULL
K	NULL
K	NULL
MOUSE	NULL
HUMAN	NULL
343	NULL
TGC	NULL
TCT	NULL
CCC	NULL
AAA	NULL
ACA	NULL
GAT	NULL
TAG	NULL
361	NULL
115	NULL
C	NULL
S	NULL
[	NULL
e	NULL
]	NULL
K	NULL
T	NULL
K	NULL
*	NULL
120	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

BASIC	NULL
REGION	NULL
C	NULL
G	NULL
T	NULL
T	NULL
C	NULL
TAT	NULL
GTA	NULL
AAA	NULL
TGT	NULL
CTG	NULL
GAG	NULL
AGC	NULL
CGA	NULL
GTT	NULL
GCA	NULL
285	NULL
¥||	NULL
v	NULL
K	NULL
Oc	NULL
OL	NULL
B	NULL
S	NULL
RO	NULL
V	NULL
A	NULL
=	NULL
95	NULL
—	NULL
“	NULL
—LEUCINE	NULL
ZIPPER	NULL
--	NULL
--	NULL
-G	NULL
T	NULL
ATA	NULL
GAG	NULL
GAA	NULL
CTT	NULL
GAA	NULL
ACC	NULL
TTG	NULL
AAA	NULL
GAC	NULL
ATT	NULL
342	NULL
I	NULL
E	NULL
E	NULL
L	NULL
E	NULL
T	NULL
L	NULL
K	NULL
D	NULL
I	NULL
114	NULL
LEUCINE	NULL
ZIPPER	NULL
--	NULL
-	NULL
ICER	NULL
cDNA	NULL
sequences	NULL
obtained	NULL
from	NULL
forskolin-induced	NULL
Jurkat	NULL
T-cell	NULL
RNA	NULL
by	NULL
RT-PCR	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
CREM	NULL
gene	NULL
.	NULL

The	NULL
alternative	NULL
P1	NULL
and	NULL
cAMP-responsive	NULL
P2	NULL
promoters	NULL
are	NULL
depicted	NULL
by	NULL
arrows	NULL
.	NULL

The	NULL
BRLZa	NULL
corresponds	NULL
to	NULL
the	NULL
DNA-binding	NULL
domain	NULL
basic	NULL
leucine	NULL
zipper	NULL
bZIP	NULL
I	NULL
(	NULL
CREB-like	NULL
)	NULL
,	NULL
and	NULL
BRLZb	NULL
corresponds	NULL
to	NULL
bZIP	NULL
II	NULL
(	NULL
CREM-like	NULL
)	NULL
.	NULL

The	NULL
phosphorylation	NULL
domain	NULL
(	NULL
P-box	NULL
)	NULL
and	NULL
Q-rich	NULL
domains	NULL
are	NULL
indicated	NULL
.	NULL

RNA	NULL
splicing	NULL
generates	NULL
the	NULL
four	NULL
isoforms	NULL
of	NULL
ICER	NULL
,	NULL
with	NULL
alternatively	NULL
spliced	NULL
exons	NULL
encoding	NULL
the	NULL
DNA-binding	NULL
bZIP	NULL
domains	NULL
(	NULL
ICER	NULL
I	NULL
or	NULL
ICER	NULL
II	NULL
containing	NULL
exons	NULL
Ia	NULL
or	NULL
Ib	NULL
,	NULL
respectively	NULL
)	NULL
and	NULL
the	NULL
amino	NULL
proximal	NULL
y	NULL
exon	NULL
(	NULL
ICER	NULL
I	NULL
and	NULL
ICER	NULL
II	NULL
containing	NULL
y	NULL
exon	NULL
,	NULL
and	NULL
ICER	NULL
Iy	NULL
and	NULL
ICER	NULL
IIy	NULL
lacking	NULL
the	NULL
y	NULL
exon	NULL
)	NULL
.	NULL

All	NULL
four	NULL
isoforms	NULL
of	NULL
ICER	NULL
are	NULL
schematically	NULL
represented	NULL
below	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Alignment	NULL
of	NULL
human	NULL
and	NULL
mouse	NULL
homologues	NULL
of	NULL
ICER	NULL
II	NULL
cDNAs	NULL
.	NULL

Upper	NULL
numbers	NULL
in	NULL
the	NULL
margins	NULL
refer	NULL
to	NULL
adjacent	NULL
nucleotides	NULL
;	NULL
lower	NULL
numbers	NULL
in	NULL
the	NULL
margin	NULL
are	NULL
amino	NULL
acids	NULL
.	NULL

The	NULL
+1	NULL
corresponds	NULL
to	NULL
A	NULL
of	NULL
the	NULL
ATG	NULL
initiation	NULL
codon	NULL
.	NULL

Single-point	NULL
nucleotide	NULL
substitutions	NULL
outside	NULL
of	NULL
the	NULL
bZIP	NULL
II	NULL
domain	NULL
yielded	NULL
three	NULL
amino	NULL
acid	NULL
changes	NULL
between	NULL
human	NULL
and	NULL
mouse	NULL
homologues	NULL
in	NULL
positions	NULL
Glu	NULL
'	NULL
3-Asp	NULL
,	NULL
Arg*	NULL
``	NULL
-GIn	NULL
,	NULL
and	NULL
Ala*®-Thr	NULL
,	NULL
framed	NULL
in	NULL
squares	NULL
.	NULL

The	NULL
cDNA	NULL
sequences	NULL
of	NULL
the	NULL
three	NULL
other	NULL
human	NULL
ICER	NULL
isoforms	NULL
that	NULL
were	NULL
cloned	NULL
and	NULL
sequenced	NULL
from	NULL
human	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
ICER	NULL
IIy	NULL
,	NULL
ICER	NULL
I	NULL
,	NULL
and	NULL
ICER	NULL
Iy	NULL
)	NULL
are	NULL
not	NULL
shown	NULL
.	NULL

strong	NULL
ICER	NULL
IIy	NULL
and	NULL
weaker	NULL
ICER	NULL
II-specific	NULL
mRNA	NULL
signals	NULL
with	NULL
the	NULL
human	NULL
ICER	NULL
II	NULL
RNA	NULL
probe	NULL
(	NULL
probe	NULL
2	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
no	NULL
significant	NULL
forskolin-mediated	NULL
induction	NULL
of	NULL
ICER	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
either	NULL
cortical	NULL
thymocytes	NULL
or	NULL
unfractionated	NULL
(	NULL
total	NULL
)	NULL
human	NULL
thymocytes	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
correlate	NULL
with	NULL
the	NULL
differences	NULL
in	NULL
cAMP	NULL
levels	NULL
observed	NULL
after	NULL
treating	NULL
medullary	NULL
and	NULL
cortical	NULL
thymocytes	NULL
with	NULL
forskolin	NULL
(	NULL
Fig	NULL
.	NULL

1F	NULL
)	NULL
and	NULL
confirm	NULL
that	NULL
ICER	NULL
induction	NULL
can	NULL
be	NULL
detected	NULL
only	NULL
in	NULL
a	NULL
subset	NULL
of	NULL
mature	NULL
medullary	NULL
thymocytes	NULL
.	NULL

Of	NULL
importance	NULL
is	NULL
that	NULL
ICER	NULL
is	NULL
transcribed	NULL
and	NULL
translated	NULL
exclusively	NULL
from	NULL
an	NULL
internal	NULL
promoter	NULL
(	NULL
P2	NULL
)	NULL
whose	NULL
activity	NULL
is	NULL
stimulated	NULL
by	NULL
cAMP-responsive	NULL
autoregulatory	NULL
enhancers	NULL
(	NULL
3	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
ICER	NULL
is	NULL
the	NULL
only	NULL
CREM	NULL
isoform	NULL
induced	NULL
in	NULL
thymocytes	NULL
and	NULL
that	NULL
the	NULL
constitutive	NULL
P1	NULL
promoter	NULL
is	NULL
not	NULL
used	NULL
,	NULL
a	NULL
human	NULL
CREMy	NULL
probe	NULL
(	NULL
probe	NULL
1	NULL
)	NULL
that	NULL
contains	NULL
exons	NULL
from	NULL
the	NULL
5	NULL
'	NULL
portion	NULL
of	NULL
the	NULL
CREM	NULL
gene	NULL
upstream	NULL
of	NULL
the	NULL
ICER	NULL
-specific	NULL
P2	NULL
promoter	NULL
was	NULL
used	NULL
in	NULL
the	NULL
RNase	NULL
protection	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
and	NULL
C	NULL
)	NULL
.	NULL

The	NULL
length	NULL
of	NULL
protected	NULL
ICER	NULL
IIy	NULL
fragment	NULL
by	NULL
the	NULL
CREM	NULL
y	NULL
probe	NULL
corresponded	NULL
exactly	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
the	NULL
ICER	NULL
II	NULL
RNA	NULL
probe	NULL
,	NULL
indicating	NULL
the	NULL
absence	NULL
of	NULL
5	NULL
sequences	NULL
(	NULL
P1	NULL
promoter	NULL
induced	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
P2	NULL
promoter	NULL
in	NULL
forskolin-induced	NULL
CREM	NULL
transcripts	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
ICER	NULL
Hy	NULL
is	NULL
the	NULL
prevalent	NULL
CREM	NULL
isoform	NULL
in	NULL
the	NULL
forskolin-treated	NULL
Jurkat	NULL
leukemic	NULL
T-cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Autoregulatory	NULL
Inhibition	NULL
of	NULL
ICER	NULL
in	NULL
T	NULL
Cells	NULL
.	NULL

Since	NULL
ICER	NULL
expressed	NULL
in	NULL
medullary	NULL
thymocytes	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
specifically	NULL
uses	NULL
the	NULL
cAMP-responsive	NULL
P2	NULL
promoter	NULL
in	NULL
the	NULL
human	NULL
CREM	NULL
gene	NULL
,	NULL
we	NULL
questioned	NULL
whether	NULL
an	NULL
autoregulatory	NULL
loop	NULL
,	NULL
similar	NULL
to	NULL
that	NULL
described	NULL
in	NULL
the	NULL
pineal	NULL
and	NULL
pituitary	NULL
glands	NULL
Medical	NULL
Sciences	NULL
:	NULL
Bodor	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
3539	NULL
FSK	NULL
_	NULL
PGE	NULL
,	NULL
fe	NULL
m	NULL
A	NULL
0	NULL
ih	NULL
3h	NULL
'	NULL
o	NULL
1h	NULL
3h	NULL
|	NULL
--	NULL
DNA-Binding	NULL
|	NULL
GENE—I	NULL
:	NULL
T1	NULL
Q-Rich	NULL
_	NULL
--	NULL
P-Box	NULL
--	NULL
-|	NULL
_	NULL
-Rich	NULL
P2	NULL
BR	NULL
LZa	NULL
LZb	NULL
*	NULL
LA	NULL
‘	NULL
VHBHcHEllﬂieillcerl3	NULL
'	NULL
agen	NULL
»	NULL
a	NULL
U	NULL
%	NULL
I	NULL
Y¥_raa	NULL
TAG	NULL
gum	NULL
.	NULL

:	NULL
+383	NULL
ATG	NULL
ATG	NULL
'	NULL
+302	NULL
w	NULL
»	NULL
(	NULL
ICERIy	NULL
)	NULL
Proper	NULL
[	NULL
_s	NULL
|	NULL
e	NULL
|	NULL
r	NULL
|	NULL
n	NULL
|	NULL
m	NULL
|	NULL
-	NULL
+227	NULL
a	NULL
(	NULL
ICER1T	NULL
)	NULL
3	NULL
e	NULL
Protected	NULL
657	NULL
CREMy	NULL
bound	NULL
``	NULL
~	NULL
Fragments	NULL
a	NULL
+166	NULL
|	NULL
I	NULL
--	NULL
--	NULL
--	NULL
I	NULL
302	NULL
ICERIH	NULL
,	NULL
ICERIy	NULL
(	NULL
ICERIy	NULL
)	NULL
--	NULL
-	NULL
16s	NULL
1cERI	NULL
,	NULL
icEeRy	NULL
*	NULL
e	NULL
g	NULL
Protected	NULL
363	NULL
ICERII	NULL
Fragments	NULL
k	NULL
--	NULL
--	NULL
-|	NULL
302	NULL
ICERIly	NULL
J	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-	NULL
227	NULL
ICERI	NULL
s	NULL
--	NULL
-	NULL
166	NULL
p	NULL
+	NULL
GePD	NULL
B	NULL
§	NULL
a	NULL
a	NULL
C	NULL
_	NULL
s	NULL
D	NULL
§	NULL
op	NULL
of	NULL
or	NULL
e	NULL
e	NULL
8	NULL
z-	NULL
£	NULL
o	NULL
9	NULL
E	NULL
@	NULL
E	NULL
go	NULL
s	NULL
E	NULL
p	NULL
£	NULL
13	NULL
5	NULL
g	NULL
03	NULL
:	NULL
19	NULL
)	NULL
>	NULL
g	NULL
a	NULL
3	NULL
5	NULL
§	NULL
3	NULL
A	NULL
s	NULL
3	NULL
a	NULL
0	NULL
x	NULL
<	NULL
€	NULL
%	NULL
§	NULL
2	NULL
o	NULL
i-	NULL
=	NULL
£	NULL
o	NULL
u	NULL
.	NULL

&	NULL
0	NULL
u.	NULL
O	NULL
&	NULL
T	NULL
%	NULL
,	NULL
;	NULL
-	NULL
I	NULL
.	NULL

T	NULL
I	NULL
:	NULL
'	NULL
FSK	NULL
&	NULL
&	NULL
&	NULL
'	NULL
o	NULL
ao	NULL
insn	NULL
``	NULL
o	NULL
30	NULL
th	NULL
3h	NULL
'	NULL
o	NULL
30°	NULL
th	NULL
3h	NULL
sh	NULL
FSK	NULL
cs	NULL
``	NULL
65	NULL
/	NULL
>	NULL
mes	NULL
(	NULL
ICERIN	NULL
)	NULL
363+	NULL
402	NULL
»	NULL
(	NULL
CERI	NULL
)	NULL
+302	NULL
®	NULL
*	NULL
+363	NULL
out	NULL
(	NULL
ICERIy	NULL
)	NULL
{	NULL
CERN	NULL
)	NULL
as	NULL
==	NULL
+302	NULL
270	NULL
>	NULL
-	NULL
Ms	NULL
(	NULL
IcERty	NULL
»	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
910	NULL
111213	NULL
14	NULL
a-globin	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
I	NULL
+~GePD	NULL
rps	NULL
P	NULL
+GSPD	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
1011	NULL
12	NULL
13141516	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Differential	NULL
inducibility	NULL
of	NULL
ICER	NULL
transcripts	NULL
during	NULL
T-cell	NULL
development	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
probes	NULL
used	NULL
in	NULL
ICER	NULL
RNA	NULL
analysis	NULL
by	NULL
RNase	NULL
protection	NULL
assays	NULL
.	NULL

The	NULL
DNA-binding	NULL
domains	NULL
and	NULL
the	NULL
phosphorylated	NULL
region	NULL
(	NULL
P-box	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
partially	NULL
protected	NULL
probes	NULL
obtained	NULL
during	NULL
the	NULL
RNase	NULL
protection	NULL
analysis	NULL
is	NULL
indicated	NULL
by	NULL
horizontal	NULL
bars	NULL
.	NULL

Probe	NULL
1	NULL
corresponds	NULL
to	NULL
human	NULL
CREMy	NULL
(	NULL
13	NULL
)	NULL
,	NULL
initiated	NULL
at	NULL
the	NULL
P1	NULL
promoter	NULL
.	NULL

Probe	NULL
2	NULL
corresponds	NULL
to	NULL
human	NULL
ICER	NULL
II	NULL
,	NULL
initiated	NULL
at	NULL
the	NULL
P2	NULL
promoter	NULL
.	NULL

The	NULL
sizes	NULL
in	NULL
nucleotides	NULL
of	NULL
the	NULL
protected	NULL
RNA	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RNase	NULL
protection	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
medullary	NULL
,	NULL
cortical	NULL
,	NULL
or	NULL
total	NULL
thymocytes	NULL
treated	NULL
with	NULL
forskolin	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
(	NULL
lanes	NULL
4-15	NULL
)	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
from	NULL
Jurkat	NULL
cells	NULL
after	NULL
3	NULL
h	NULL
of	NULL
forskolin	NULL
treatment	NULL
(	NULL
lane	NULL
16	NULL
)	NULL
.	NULL

The	NULL
sizes	NULL
of	NULL
the	NULL
bands	NULL
,	NULL
corresponding	NULL
to	NULL
specific	NULL
ICER-protected	NULL
fragments	NULL
,	NULL
are	NULL
shown	NULL
(	NULL
nt	NULL
)	NULL
.	NULL

Asterisks	NULL
denote	NULL
nonspecific	NULL
background	NULL
bands	NULL
.	NULL

The	NULL
bands	NULL
of	NULL
363	NULL
nt	NULL
and	NULL
302	NULL
nt	NULL
correspond	NULL
to	NULL
ICER	NULL
II	NULL
and	NULL
ICER	NULL
IIy	NULL
,	NULL
respectively	NULL
;	NULL
both	NULL
contain	NULL
the	NULL
bZIP	NULL
II	NULL
domain	NULL
.	NULL

Probe	NULL
2	NULL
(	NULL
402	NULL
nt	NULL
)	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
internal	NULL
probe	NULL
of	NULL
a-globin	NULL
(	NULL
270	NULL
nt	NULL
)	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
did	NULL
not	NULL
yield	NULL
any	NULL
detectable	NULL
signal	NULL
with	NULL
tRNA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
band	NULL
of	NULL
133	NULL
nt	NULL
corresponds	NULL
to	NULL
the	NULL
protected	NULL
fragment	NULL
of	NULL
the	NULL
a-globin	NULL
probe	NULL
.	NULL

The	NULL
enhancement	NULL
of	NULL
the	NULL
270-nt	NULL
«	NULL
-globin	NULL
band	NULL
in	NULL
the	NULL
total	NULL
thymocyte	NULL
RNA	NULL
1	NULL
h	NULL
after	NULL
treatment	NULL
with	NULL
forskolin	NULL
is	NULL
unexplained	NULL
.	NULL

(	NULL
C	NULL
)	NULL
ICER	NULL
expression	NULL
is	NULL
induced	NULL
specifically	NULL
by	NULL
the	NULL
cAMP	NULL
signal	NULL
transduction	NULL
pathway	NULL
.	NULL

ICER	NULL
expression	NULL
following	NULL
6	NULL
h	NULL
of	NULL
treatment	NULL
was	NULL
scored	NULL
with	NULL
probe	NULL
1	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
in	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
(	NULL
0	NULL
;	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
0.1	NULL
mM	NULL
forskolin	NULL
(	NULL
FSK	NULL
;	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
10	NULL
ug/ml	NULL
PMA	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
10	NULL
ug/ml	NULL
cycloheximide	NULL
(	NULL
CHX	NULL
;	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
cycloheximide	NULL
in	NULL
combination	NULL
with	NULL
forskolin	NULL
(	NULL
FSK	NULL
+	NULL
CHX	NULL
;	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
10~	NULL
``	NULL
M	NULL
dexamethasone	NULL
(	NULL
DEX	NULL
;	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
10	NULL
ug/ml	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

ICER	NULL
expression	NULL
is	NULL
induced	NULL
only	NULL
upon	NULL
stimulation	NULL
of	NULL
the	NULL
cAMP	NULL
pathway	NULL
by	NULL
forskolin	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
after	NULL
co-treatment	NULL
with	NULL
cycloheximide	NULL
,	NULL
which	NULL
resulted	NULL
in	NULL
superinduction	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

No	NULL
products	NULL
corresponding	NULL
to	NULL
utilization	NULL
of	NULL
the	NULL
P1	NULL
promoter	NULL
were	NULL
detected	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Immediate	NULL
,	NULL
early	NULL
ICER	NULL
expression	NULL
is	NULL
specifically	NULL
induced	NULL
in	NULL
T-cell	NULL
lines	NULL
,	NULL
but	NULL
not	NULL
in	NULL
B-cell	NULL
lines	NULL
.	NULL

RNase	NULL
protection	NULL
analysis	NULL
of	NULL
ICER	NULL
expression	NULL
(	NULL
probe	NULL
2	NULL
)	NULL
in	NULL
five	NULL
different	NULL
T-cell	NULL
lines	NULL
and	NULL
two	NULL
different	NULL
B-cell	NULL
lines	NULL
,	NULL
either	NULL
untreated	NULL
or	NULL
after	NULL
3	NULL
h	NULL
of	NULL
forskolin	NULL
treatment	NULL
,	NULL
shows	NULL
induction	NULL
of	NULL
ICER	NULL
IIy	NULL
(	NULL
302	NULL
nt	NULL
)	NULL
and	NULL
ICER	NULL
II	NULL
(	NULL
363	NULL
nt	NULL
)	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
MOLT3	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
MOLT4	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
HUT78	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
,	NULL
and	NULL
CEM	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

ICER	NULL
induction	NULL
was	NULL
only	NULL
faintly	NULL
detectable	NULL
under	NULL
these	NULL
conditions	NULL
in	NULL
the	NULL
B-cell	NULL
lines	NULL
X-50-7	NULL
(	NULL
11	NULL
)	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
,	NULL
and	NULL
AKATA	NULL
(	NULL
12	NULL
)	NULL
(	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
.	NULL

T-cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
.	NULL

(	NULL
£	NULL
)	NULL
ICER	NULL
expression	NULL
in	NULL
PBL	NULL
T	NULL
cells	NULL
is	NULL
downregulated	NULL
by	NULL
forskolin	NULL
(	NULL
0.1	NULL
mM	NULL
)	NULL
,	NULL
but	NULL
upregulated	NULL
by	NULL
PGE	NULL
;	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
.	NULL

After	NULL
1	NULL
h	NULL
,	NULL
forskolin	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
PGE	NULL
;	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
caused	NULL
significant	NULL
diminution	NULL
or	NULL
enhancement	NULL
of	NULL
ICER	NULL
expression	NULL
in	NULL
PBL	NULL
T	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
significant	NULL
shift	NULL
from	NULL
ICER	NULL
II	NULL
(	NULL
302	NULL
and	NULL
363	NULL
nt	NULL
)	NULL
to	NULL
ICER	NULL
I	NULL
(	NULL
227	NULL
and	NULL
166	NULL
nt	NULL
)	NULL
isoforms	NULL
was	NULL
also	NULL
observed	NULL
after	NULL
PGE	NULL
»	NULL
treatment	NULL
.	NULL

ICER	NULL
expression	NULL
was	NULL
scored	NULL
by	NULL
RNase	NULL
protection	NULL
analysis	NULL
using	NULL
probe	NULL
2	NULL
.	NULL

Equal	NULL
loading	NULL
and	NULL
quality	NULL
of	NULL
RNA	NULL
were	NULL
monitored	NULL
cither	NULL
by	NULL
using	NULL
human	NULL
a-globin	NULL
as	NULL
an	NULL
internal	NULL
probe	NULL
(	NULL
protected	NULL
fragment	NULL
133	NULL
nt	NULL
)	NULL
(	NULL
14	NULL
)	NULL
or	NULL
by	NULL
G6PD	NULL
RT-PCR	NULL
controls	NULL
(	NULL
15	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
a	NULL
series	NULL
of	NULL
many	NULL
experiments	NULL
.	NULL

3540	NULL
Medical	NULL
Sciences	NULL
:	NULL
Bodor	NULL
et	NULL
al	NULL
.	NULL

IMMUNE	NULL
PREIMMUNE	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
ICER	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Immunocytochemical	NULL
analysis	NULL
of	NULL
forskolin-treated	NULL
Jurkat	NULL
T	NULL
cells	NULL
after	NULL
24	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
forskolin	NULL
reveals	NULL
intense	NULL
staining	NULL
in	NULL
nuclei	NULL
with	NULL
ICER-specific	NULL
antiserum	NULL
,	NULL
but	NULL
no	NULL
detectable	NULL
staining	NULL
with	NULL
pre-immune	NULL
serum	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
forskolin	NULL
(	NULL
0.1	NULL
mM	NULL
)	NULL
and	NULL
attached	NULL
to	NULL
slides	NULL
after	NULL
24	NULL
h.	NULL
Immunocytochemistry	NULL
was	NULL
performed	NULL
with	NULL
ICER	NULL
specific	NULL
antiserum	NULL
raised	NULL
in	NULL
guinea	NULL
pigs	NULL
against	NULL
a	NULL
synthetic	NULL
ICER-specific	NULL
peptide	NULL
(	NULL
Ala-Val-Thr-Gly-Asp-Glu-Thr-Gly-Gly-Cys	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
using	NULL
horseradish	NULL
peroxidase	NULL
.	NULL

Preabsorption	NULL
of	NULL
ICER-specific	NULL
antisera	NULL
with	NULL
the	NULL
ICER	NULL
peptide	NULL
(	NULL
100	NULL
ug/m	NULL
!	NULL
)	NULL

abolished	NULL
the	NULL
immunostaining	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

of	NULL
rodents	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
,	NULL
results	NULL
from	NULL
ICER	NULL
binding	NULL
to	NULL
its	NULL
own	NULL
promoter	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
cAMP	NULL
signaling	NULL
pathway	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
P2	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
was	NULL
therefore	NULL
examined	NULL
.	NULL

Activation	NULL
of	NULL
signal	NULL
transduction	NULL
pathways	NULL
other	NULL
than	NULL
the	NULL
cAMP	NULL
pathway	NULL
by	NULL
treatment	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
dexamethasone	NULL
,	NULL
or	NULL
phytohemagglutinin	NULL
,	NULL
did	NULL
not	NULL
induce	NULL
ICER	NULL
mRNAs	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
cycloheximide	NULL
markedly	NULL
potentiated	NULL
the	NULL
forskolin-induced	NULL
elevation	NULL
of	NULL
ICER	NULL
mRNA	NULL
(	NULL
FSK+CHX	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
ICER	NULL
synthesis	NULL
by	NULL
cycloheximide	NULL
in	NULL
T	NULL
cells	NULL
renders	NULL
ICER	NULL
unavailable	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
P2	NULL
promoter	NULL
,	NULL
and	NULL
are	NULL
consistent	NULL
with	NULL
autoregulatory	NULL
inhibition	NULL
,	NULL
as	NULL
described	NULL
in	NULL
the	NULL
rodent	NULL
model	NULL
(	NULL
3	NULL
)	NULL
.	NULL

ICER	NULL
Is	NULL
Expressed	NULL
Preferentially	NULL
in	NULL
T	NULL
Cells	NULL
.	NULL

Induction	NULL
of	NULL
immediate	NULL
,	NULL
early	NULL
expression	NULL
of	NULL
ICER	NULL
mRNA	NULL
after	NULL
3	NULL
h	NULL
of	NULL
forskolin	NULL
treatment	NULL
was	NULL
detected	NULL
in	NULL
all	NULL
five	NULL
human	NULL
T-cell	NULL
lines	NULL
tested	NULL
(	NULL
Jurkat	NULL
,	NULL
MOLT-3	NULL
,	NULL
MOLT-4	NULL
,	NULL
HUT78	NULL
,	NULL
and	NULL
CEM	NULL
)	NULL
,	NULL
whereas	NULL
ICER	NULL
was	NULL
only	NULL
faintly	NULL
detectable	NULL
in	NULL
the	NULL
B-cell	NULL
lines	NULL
(	NULL
X-50-7	NULL
and	NULL
AKATA	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
an	NULL
immediate	NULL
,	NULL
early	NULL
T-cell	NULL
preferential	NULL
expression	NULL
of	NULL
ICER	NULL
.	NULL

Moreover	NULL
,	NULL
a	NULL
marked	NULL
increase	NULL
of	NULL
ICER	NULL
mRNA	NULL
levels	NULL
was	NULL
observed	NULL
in	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
purified	NULL
human	NULL
PBL	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
PGE	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

3€	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
a	NULL
shift	NULL
in	NULL
the	NULL
prevalence	NULL
of	NULL
isoforms	NULL
was	NULL
observed	NULL
:	NULL
ICER	NULL
II	NULL
and	NULL
ICER	NULL
IIy	NULL
shifted	NULL
to	NULL
ICER	NULL
Iy	NULL
and	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
to	NULL
ICER	NULL
I	NULL
.	NULL

In	NULL
these	NULL
mature	NULL
PBL	NULL
T	NULL
cells	NULL
,	NULL
a	NULL
forskolin-mediated	NULL
inhibition	NULL
of	NULL
ICER	NULL
mRNA	NULL
levels	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
mechanism	NULL
of	NULL
autoregulatory	NULL
inhibition	NULL
of	NULL
the	NULL
P2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

3E	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
ICER	NULL
mRNA	NULL
observed	NULL
in	NULL
untreated	NULL
,	NULL
purified	NULL
PBL	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
either	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
cAMP	NULL
signaling	NULL
pathways	NULL
during	NULL
the	NULL
preparation	NULL
of	NULL
T	NULL
lymphocytes	NULL
,	NULL
or	NULL
may	NULL
reflect	NULL
a	NULL
normal	NULL
physiologic	NULL
property	NULL
of	NULL
resting	NULL
PBL	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
conjecture	NULL
correlates	NULL
with	NULL
the	NULL
elevated	NULL
basal	NULL
levels	NULL
of	NULL
cAMP	NULL
observed	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
PGE	NULL
;	NULL
or	NULL
forskolin	NULL
(	NULL
note	NULL
the	NULL
difference	NULL
in	NULL
zero	NULL
time	NULL
points	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
E	NULL
and	NULL
G	NULL
)	NULL
.	NULL

A	NULL
further	NULL
activation	NULL
of	NULL
the	NULL
cAMP	NULL
pathway	NULL
by	NULL
forskolin	NULL
is	NULL
predicted	NULL
to	NULL
repress	NULL
ICER	NULL
mRNA	NULL
levels	NULL
via	NULL
the	NULL
negative	NULL
autoregulatory	NULL
actions	NULL
of	NULL
the	NULL
ICER	NULL
repressor	NULL
of	NULL
the	NULL
P2	NULL
promoter	NULL
.	NULL

The	NULL
inducibility	NULL
of	NULL
the	NULL
ICER	NULL
promoter	NULL
under	NULL
physiological	NULL
conditions	NULL
in	NULL
vitro	NULL
suggests	NULL
an	NULL
important	NULL
role	NULL
of	NULL
ICER	NULL
in	NULL
T-cell	NULL
functions	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
specific	NULL
expression	NULL
of	NULL
ICER	NULL
protein	NULL
,	NULL
directed	NULL
by	NULL
the	NULL
cAMP-responsive	NULL
P2	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
in	NULL
sity	NULL
immunocytochemical	NULL
analysis	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
with	NULL
an	NULL
antiserum	NULL
raised	NULL
against	NULL
a	NULL
synthetic	NULL
peptide	NULL
that	NULL
corresponds	NULL
to	NULL
the	NULL
ICER-specific	NULL
exon	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
is	NULL
present	NULL
in	NULL
ICER	NULL
,	NULL
but	NULL
not	NULL
other	NULL
CREM	NULL
proteins	NULL
.	NULL

Detection	NULL
of	NULL
ICER	NULL
after	NULL
24	NULL
h	NULL
of	NULL
forskolin	NULL
treatment	NULL
indicates	NULL
a	NULL
relatively	NULL
high	NULL
stability	NULL
of	NULL
the	NULL
protein	NULL
expressed	NULL
in	NULL
the	NULL
T	NULL
cells	NULL
.	NULL

ICER	NULL
Inhibits	NULL
Calcineurin-Mediated	NULL
IL-2	NULL
Expression	NULL
.	NULL

PGE	NULL
;	NULL
is	NULL
one	NULL
of	NULL
the	NULL
numerous	NULL
physiologic	NULL
inhibitors	NULL
of	NULL
T-cell	NULL
proliferation	NULL
that	NULL
elevate	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

PGE	NULL
;	NULL
is	NULL
also	NULL
known	NULL
to	NULL
inhibit	NULL
IL-2	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
counteracting	NULL
calcineurin-dependent	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
mediated	NULL
by	NULL
the	NULL
cooperative	NULL
interactions	NULL
of	NULL
transcription	NULL
factors	NULL
NFAT	NULL
and	NULL
the	NULL
Fos/Jun	NULL
(	NULL
AP-1	NULL
)	NULL
complex	NULL
(	NULL
18-20	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
ICER	NULL
expression	NULL
could	NULL
supplant	NULL
the	NULL
effect	NULL
of	NULL
PGE	NULL
;	NULL
in	NULL
the	NULL
downregulation	NULL
of	NULL
the	NULL
activated	NULL
IL-2	NULL
promoter	NULL
,	NULL
ICER	NULL
II	NULL
,	NULL
and	NULL
,	NULL
as	NULL
a	NULL
control	NULL
,	NULL
a	NULL
DNA-binding	NULL
deficient	NULL
mutated	NULL
ICER	NULL
II	NULL
without	NULL
the	NULL
leucine	NULL
zipper	NULL
(	NULL
ICER	NULL
II	NULL
LZ~	NULL
)	NULL
,	NULL
were	NULL
expressed	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
.	NULL

Expression	NULL
of	NULL
ICER	NULL
II	NULL
downregulated	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
activated	NULL
by	NULL
the	NULL
combined	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
(	NULL
PMA+1I	NULL
)	NULL
,	NULL
a	NULL
treatment	NULL
known	NULL
to	NULL
activate	NULL
the	NULL
calcineurin-dependent	NULL
signal	NULL
pathway	NULL
(	NULL
18	NULL
)	NULL
,	NULL
whereas	NULL
expression	NULL
of	NULL
the	NULL
mutated	NULL
ICER	NULL
II	NULL
LZ~	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
ICER	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
,	NULL
and	NULL
substituted	NULL
for	NULL
,	NULL
PGE	NULL
;	NULL
in	NULL
the	NULL
transcriptional	NULL
downregu-	NULL
a	NULL
z	NULL
-	NULL
4	NULL
727	NULL
4p	NULL
Bou	NULL
B	NULL
|	NULL
Tax	NULL
-	NULL
a	NULL
ep	NULL
C	NULL
peas	NULL
,	NULL
ICERII	NULL
-	NULL
-	NULL
op	NULL
-	NULL
p	NULL
-	NULL
p	NULL
-	NULL
ICERII	NULL
-	NULL
-	NULL
4	NULL
-	NULL
p	NULL
-	NULL
4	NULL
-	NULL
ICERII	NULL
-_	NULL
-	NULL
;	NULL
ICERIMILZ	NULL
-	NULL
-	NULL
-	NULL
p	NULL
-	NULL
po-	NULL
p	NULL
ICERIILZ	NULL
-	NULL
-	NULL
-	NULL
p	NULL
-	NULL
p	NULL
-	NULL
4	NULL
ICERMLZ	NULL
-	NULL
-	NULL
-	NULL
4	NULL
#	NULL
#	NULL
a	NULL
#	NULL
@	NULL
N0	NULL
0	NULL
8	NULL
2	NULL
-	NULL
#	NULL
de	NULL
wn	NULL
6	NULL
Oe	NULL
@	NULL
0	NULL
@	NULL
0000	NULL
****®*	NULL
%	NULL
il	NULL
nf	NULL
hon	NULL
1°	NULL
2	NULL
3	NULL
4	NULL
506	NULL
7	NULL
8	NULL
oce	NULL
1	NULL
2	NULL
3	NULL
4	NULL
IL-2-CAT	NULL
CR-CAT	NULL
CR-CAT	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

ICER	NULL
represses	NULL
calcineurin-dependent	NULL
activity	NULL
of	NULL
IL-2	NULL
promoter	NULL
and	NULL
Tax	NULL
or	NULL
PKA-mediated	NULL
HTLV-I	NULL
transactivation	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
either	NULL
the	NULL
human	NULL
IL-2-CAT	NULL
reporter	NULL
(	NULL
20	NULL
)	NULL
or	NULL
with	NULL
the	NULL
HTLV-I	NULL
LTR-CAT	NULL
(	NULL
CR-CAT	NULL
)	NULL
reporter	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
(	NULL
21	NULL
)	NULL
.	NULL

To	NULL
activate	NULL
the	NULL
calcineurin-dependent	NULL
signal	NULL
pathway	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
ionomycin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
16	NULL
h	NULL
posttransfection	NULL
(	NULL
PMA+1	NULL
)	NULL
;	NULL
to	NULL
induce	NULL
the	NULL
HTLV-I	NULL
promoter	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
of	NULL
Tax	NULL
(	NULL
21	NULL
)	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
(	NULL
22	NULL
)	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Co-transfection	NULL
with	NULL
2	NULL
,	NULL
4	NULL
,	NULL
or	NULL
8	NULL
ug	NULL
of	NULL
the	NULL
ICER	NULL
II	NULL
expression	NULL
vector	NULL
(	NULL
pKWJL5	NULL
)	NULL
represses	NULL
promoter	NULL
activation	NULL
(	NULL
A	NULL
and	NULL
B	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

No	NULL
comparable	NULL
repression	NULL
can	NULL
be	NULL
seen	NULL
with	NULL
the	NULL
DNA-binding	NULL
deficient	NULL
ICER	NULL
mutant	NULL
,	NULL
ICER	NULL
II	NULL
LZ~-expression	NULL
vector	NULL
in	NULL
parallel	NULL
transfections	NULL
using	NULL
the	NULL
same	NULL
amounts	NULL
of	NULL
DNA	NULL
(	NULL
4	NULL
and	NULL
B	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
PKA	NULL
activated	NULL
CR-CAT	NULL
reporter	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
is	NULL
almost	NULL
completely	NULL
repressed	NULL
by	NULL
2	NULL
ug	NULL
of	NULL
ICER	NULL
II	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
specificity	NULL
of	NULL
ICER	NULL
inhibition	NULL
,	NULL
pGI2	NULL
(	NULL
3XGAL4	NULL
)	NULL
-CAT	NULL
reporter	NULL
(	NULL
23	NULL
)	NULL
was	NULL
transactivated	NULL
by	NULL
the	NULL
GAL4VP16	NULL
(	NULL
24	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
ICER	NULL
II	NULL
and	NULL
ICER	NULL
II	NULL
LZ~	NULL
expression	NULL
vectors	NULL
.	NULL

No	NULL
significant	NULL
inhibition	NULL
in	NULL
transient	NULL
transfections	NULL
with	NULL
any	NULL
of	NULL
the	NULL
above-mentioned	NULL
plasmids	NULL
was	NULL
observed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Bodor	NULL
et	NULL
al	NULL
.	NULL

lation	NULL
of	NULL
the	NULL
calcineurin-dependent	NULL
,	NULL
NFAT/AP-1-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
when	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Although	NULL
transcription	NULL
factors	NULL
other	NULL
than	NULL
ICER	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
expression	NULL
by	NULL
cAMP	NULL
generating	NULL
agogists	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
support	NULL
the	NULL
idea	NULL
that	NULL
ICER	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
.	NULL

The	NULL
similarities	NULL
between	NULL
the	NULL
bZIP	NULL
domains	NULL
of	NULL
ICER	NULL
and	NULL
Fos/Jun	NULL
suggests	NULL
the	NULL
possibility	NULL
that	NULL
ICER	NULL
may	NULL
interfere	NULL
with	NULL
Fos/Jun	NULL
in	NULL
the	NULL
NFAT	NULL
complex	NULL
,	NULL
and	NULL
so	NULL
inhibit	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

ICER	NULL
Downregulates	NULL
Tax-Mediated	NULL
HTLV-I	NULL
Expression	NULL
.	NULL

The	NULL
Tax	NULL
protein	NULL
encoded	NULL
by	NULL
HTLV-I	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
enhance	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
bZIP	NULL
transcription	NULL
factors	NULL
(	NULL
25	NULL
)	NULL
,	NULL
such	NULL
as	NULL
the	NULL
strongly	NULL
cAMP-responsive	NULL
transactivator	NULL
CREB	NULL
(	NULL
26	NULL
)	NULL
,	NULL
to	NULL
CRE-like	NULL
sequences	NULL
in	NULL
the	NULL
21-bp	NULL
repeats	NULL
contained	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
HTLV-I	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
a	NULL
role	NULL
for	NULL
ICER	NULL
in	NULL
HTLV-I-infected	NULL
T	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
the	NULL
expression	NULL
of	NULL
ICER	NULL
would	NULL
inhibit	NULL
HTLV-I	NULL
promoter	NULL
activity	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
transcriptional	NULL
assays	NULL
,	NULL
in	NULL
vivo	NULL
expression	NULL
of	NULL
ICER	NULL
II	NULL
effectively	NULL
downregulates	NULL
both	NULL
Tax-	NULL
and	NULL
PKA-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
HTLV-I	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

The	NULL
results	NULL
of	NULL
our	NULL
studies	NULL
suggest	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
ICER	NULL
by	NULL
cAMP	NULL
signaling	NULL
is	NULL
a	NULL
potentially	NULL
important	NULL
mechanism	NULL
in	NULL
the	NULL
down	NULL
regulation	NULL
of	NULL
certain	NULL
genes	NULL
in	NULL
response	NULL
to	NULL
cAMP	NULL
.	NULL

cAMP	NULL
is	NULL
known	NULL
to	NULL
inhibit	NULL
pathways	NULL
upstream	NULL
of	NULL
transcription	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
cAMP-dependent	NULL
phosphorylation	NULL
inacti-vates	NULL
Raf-1	NULL
(	NULL
27	NULL
)	NULL
.	NULL

We	NULL
suggest	NULL
,	NULL
however	NULL
,	NULL
that	NULL
ICER	NULL
could	NULL
be	NULL
a	NULL
dominant	NULL
transcriptional	NULL
repressor	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
thus	NULL
,	NULL
under	NULL
certain	NULL
circumstances	NULL
,	NULL
override	NULL
effects	NULL
on	NULL
transcription	NULL
mediated	NULL
by	NULL
other	NULL
upstream	NULL
pathways	NULL
.	NULL

The	NULL
findings	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
ICER	NULL
in	NULL
T	NULL
cells	NULL
downregulates	NULL
the	NULL
IL-2	NULL
and	NULL
HTLV-I	NULL
promoters	NULL
provides	NULL
a	NULL
potential	NULL
link	NULL
between	NULL
the	NULL
quiescent	NULL
state	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
the	NULL
persistent	NULL
latency	NULL
of	NULL
HTLV-I	NULL
.	NULL

Note	NULL
Added	NULL
in	NULL
Proof	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
recently	NULL
(	NULL
28	NULL
)	NULL
that	NULL
the	NULL
targeted	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
isoform	NULL
of	NULL
the	NULL
CRE	NULL
binding	NULL
protein	NULL
to	NULL
thymocytes	NULL
of	NULL
transgenic	NULL
mice	NULL
results	NULL
in	NULL
a	NULL
profound	NULL
proliferative	NULL
defect	NULL
characterized	NULL
by	NULL
a	NULL
markedly	NULL
decreased	NULL
IL-2	NULL
pro-duction	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
D.	NULL
Ginty	NULL
,	NULL
Dr.	NULL
J.	NULL
Jain	NULL
,	NULL
H.	NULL
Hermann	NULL
,	NULL
J.	NULL
Lin	NULL
,	NULL
and	NULL
T.	NULL
Budde	NULL
for	NULL
discussion	NULL
and	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
CA	NULL
47554	NULL
(	NULL
J.L.S	NULL
.	NULL
)	NULL

and	NULL
DK25532	NULL
(	NULL
J.F.H	NULL
.	NULL
)	NULL

.	NULL

J.F.H	NULL
.	NULL

is	NULL
an	NULL
Investigator	NULL
with	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
.	NULL

1	NULL
.	NULL

Kammer	NULL
,	NULL
G.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
9	NULL
,	NULL
222-229	NULL
.	NULL

2	NULL
.	NULL

Stehle	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Foulkes	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Molina	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Simonneaux	NULL
,	NULL
V.	NULL
,	NULL
Pevet	NULL
,	NULL
P.	NULL
&	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
365	NULL
,	NULL
314-320	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
3541	NULL
Molina	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Foulkes	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Lalli	NULL
,	NULL
E.	NULL
&	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Cell	NULL
75	NULL
,	NULL
875-886	NULL
.	NULL

Lalli	NULL
,	NULL
E.	NULL
&	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
,	NULL
9633-9637	NULL
.	NULL

Haus	NULL
,	NULL
E.	NULL
,	NULL
Lakatua	NULL
,	NULL
D.	NULL
,	NULL
Swoyer	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Sackett-Lundeen	NULL
,	NULL
L.	NULL
(	NULL
1983	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Anat	NULL
.	NULL

168	NULL
,	NULL
467-517	NULL
.	NULL

Haus	NULL
,	NULL
E.	NULL
,	NULL
Nicolan	NULL
,	NULL
G.	NULL
Y.	NULL
,	NULL
Lakatua	NULL
,	NULL
D.	NULL
&	NULL
Sackett-Lundeen	NULL
,	NULL
L.	NULL
(	NULL
1988	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Chronopharmacol	NULL
.	NULL

4	NULL
,	NULL
333-424	NULL
.	NULL

Pereira	NULL
,	NULL
P.	NULL
,	NULL
Larsson	NULL
,	NULL
E.-L.	NULL
,	NULL
Forni	NULL
,	NULL
L.	NULL
,	NULL
Bandeira	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Countinho	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82	NULL
,	NULL
7691-7695	NULL
.	NULL

Brooks	NULL
,	NULL
E.	NULL
G.	NULL
,	NULL
Schmalsteig	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Wirt	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Rosenblatt	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Adkins	NULL
,	NULL
L..	NULL
T.	NULL
,	NULL
Lookingbill	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Rudloff	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Rakusan	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

&	NULL
Goldman	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

86	NULL
,	NULL
1623-1631	NULL
.	NULL

Korman	NULL
,	NULL
L.	NULL
Y.	NULL
,	NULL
Bhathena	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Voyles	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Oie	NULL
,	NULL
H.	NULL
K.	NULL
&	NULL
Recant	NULL
,	NULL
L.	NULL
(	NULL
1985	NULL
)	NULL
Diabetes	NULL
34	NULL
,	NULL
717-723	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Lab	NULL
.	NULL

Press	NULL
,	NULL
Plainview	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

14.5-14.34	NULL
.	NULL

Philippe	NULL
,	NULL
J.	NULL
,	NULL
Drucker	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Knepel	NULL
,	NULL
W.	NULL
,	NULL
Jepeal	NULL
,	NULL
L.	NULL
,	NULL
Misulovin	NULL
,	NULL
Z	NULL
.	NULL

&	NULL
Habener	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
4877-4888	NULL
.	NULL

Robey	NULL
,	NULL
E.	NULL
&	NULL
Fowlkes	NULL
,	NULL
B.J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
675-105	NULL
.	NULL

Meyer	NULL
,	NULL
T.	NULL
E.	NULL
&	NULL
Habener	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20	NULL
,	NULL
6106	NULL
.	NULL

Charnay	NULL
,	NULL
P.	NULL
,	NULL
Treisman	NULL
,	NULL
R.	NULL
,	NULL
Mellon	NULL
,	NULL
P.	NULL
,	NULL
Chao	NULL
,	NULL
M.	NULL
,	NULL
Axel	NULL
,	NULL
R.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1984	NULL
)	NULL
Cell	NULL
38	NULL
,	NULL
251-263	NULL
.	NULL

Foulkes	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Schlotter	NULL
,	NULL
F.	NULL
,	NULL
Pevet	NULL
,	NULL
P.	NULL
&	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
362	NULL
,	NULL
264-267	NULL
.	NULL

Paul	NULL
,	NULL
W.	NULL
E.	NULL
&	NULL
Seder	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
241-251	NULL
.	NULL

Goodwin	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Bankhurst	NULL
,	NULL
A.	NULL
D.	NULL
&	NULL
Messner	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1977	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

155	NULL
,	NULL
1719-1724	NULL
.	NULL

Rappaport	NULL
,	NULL
R.S	NULL
.	NULL

&	NULL
Dodge	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

155	NULL
,	NULL
943-948	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
&	NULL
Boumpas	NULL
,	NULL
D.	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
1813-1817	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Miner	NULL
,	NULL
Z.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
365	NULL
,	NULL
352-355	NULL
.	NULL

Sodroski	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Goh	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Salahuddin	NULL
,	NULL
S.	NULL
Z.	NULL
,	NULL
Aldovini	NULL
,	NULL
A.	NULL
,	NULL
Franchini	NULL
,	NULL
G.	NULL
,	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
,	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Sug-amura	NULL
,	NULL
K.	NULL
,	NULL
Hinuma	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Haseltine	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

55	NULL
,	NULL
831-835	NULL
.	NULL

Maurer	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
6870-6873	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
Speck	NULL
,	NULL
S.	NULL
H.	NULL
&	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
6914-6918	NULL
.	NULL

Sadowski	NULL
,	NULL
I.	NULL
,	NULL
Ma	NULL
,	NULL
J.	NULL
,	NULL
Triezenberg	NULL
,	NULL
S.	NULL
&	NULL
Ptashne	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
335	NULL
,	NULL
563-564	NULL
.	NULL

Wagner	NULL
,	NULL
S.	NULL
&	NULL
Green	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
395-399	NULL
.	NULL

Brauweiler	NULL
,	NULL
A.	NULL
,	NULL
Garl	NULL
,	NULL
P.	NULL
,	NULL
Franklin	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Giebler	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

&	NULL
Nyborg	NULL
,	NULL
J.	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
12814-12820	NULL
.	NULL

Cook	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

&	NULL
McCormick	NULL
,	NULL
F.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
1069-1072	NULL
.	NULL

Barton	NULL
,	NULL
K.	NULL
,	NULL
Nuthusamy	NULL
,	NULL
N.	NULL
,	NULL
Chanyangam	NULL
,	NULL
M.	NULL
,	NULL
Fischer	NULL
,	NULL
C.	NULL
,	NULL
Clen-denin	NULL
,	NULL
C.	NULL
&	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
379	NULL
,	NULL
81-85	NULL
.	NULL

